ferumoxides (Feridex)

Subscribe to Selected New Research on ferumoxides

131 relevant articles (11 outcomes, 24 trials/studies) found for this Drug

Description: MR contrast agent; Oral Magnetic Particles (OMP) is composed of ferrite crystals supported on a resin carrier particle made of a monodisperse nonbiodegradable polymer; coated with bacterial dextran to stabilize the iron oxide core; see also ferumoxtran and ferumoxsil

Also Known As:

Feridex; AMI 25; AMI25; AquaMag100; Berlex brand of ferumoxides; Endorem; Guerbert brand of ferumoxides; Guerbet brand of ferumoxides; Oral Magnetic Particles; Resovist; SH U 555A; SHU 555A; SHU-555A; WIN 39996; dextran-coated SPIO; dextran-coated superparamagnetic iron oxide

Relationship Network

Drug Context: Research Results

Experts

1.	Ros, Pablo R: 3 articles (05/2003 - 02/2002)
2.	Choi, Dongil: 3 articles (01/2003 - 04/2002)
3.	Lee, Won Jae: 3 articles (01/2003 - 04/2002)
4.	Kim, Seung Hoon: 3 articles (01/2003 - 04/2002)
5.	Lim, Jae Hoon: 3 articles (01/2003 - 04/2002)
6.	Lee, Soon Jin: 3 articles (01/2003 - 04/2002)
7.	Kondo, Hiroshi: 2 articles (08/2004 - 01/2004)
8.	Hoshi, Hiroaki: 2 articles (08/2004 - 01/2004)
9.	Goshima, Satoshi: 2 articles (08/2004 - 01/2004)
10.	Kanematsu, Masayuki: 2 articles (08/2004 - 01/2004)

Related Diseases

1.	Hepatocellular Carcinoma (Hepatoma) 09/01/2007 - "OBJECTIVE: To investigate the diagnostic efficacy of sequentially acquired gadobenete dimeglumine-enhanced 3-dimensional dynamic magnetic resonance imaging (MRI) and Resovist-enhanced MRI for detecting hepatocellular carcinoma (HCC) by comparing with combined computed tomography (CT) hepatic arteriography (CTHA) and CT arterioportography (CTAP) using 16-slice multidetector CT. " 02/01/2001 - "OBJECTIVE: The purpose of this study was to compare ferumoxides-enhanced MR imaging with combined helical CT during arterial portography and CT hepatic arteriography for preoperative detection of hepatocellular carcinomas. " 01/01/2008 - "Detection of hepatocellular carcinoma with ferucarbotran (resovist)-enhanced breath-hold MR imaging: feasibility of 10 minute-delayed images." 03/01/2005 - "MATERIALS AND METHODS: Eighteen patients with hepatocellular carcinoma (HCC) underwent breath-hold T1-, T2-, and T2-weighted magnetic resonance (MR) images at 1.5-Tesla after ferumoxides administration. " 01/01/2004 - "Resovist for imaging of hepatocellular carcinoma in the cirrhotic liver." Order ALL the reference details at left...*
2.	Neoplasms (Cancer) 11/01/1995 - "Thus, ENDOREM is useful for preoperative staging of liver tumors due to improvement in lesion detection and delineation of the hepatic vascular system." 08/01/1995 - "Resovist improved tumor liver contrast and lesion-conspicuity, especially for lesions smaller than 1 cm. The dose of 8 mumol Fe/kg was sufficient to achieve diagnostic tumor-liver contrast. " 03/01/2000 - "In a clinical study, 10 micromol/kg of ferumoxides was given in 34 consecutive patients with 31 solid tumors. " 03/01/1997 - "CONCLUSION: In our study, ferumoxides-enhanced gradient-echo imaging was as accurate as T2-weighted spin-echo imaging for revealing malignant hepatic tumors and was superior for showing their segmental location." 12/01/2009 - "Pluronic F127-modified MNPs demonstrated sustained and enhanced contrast in the whole tumor, whereas that of Feridex IV was transient and confined to the tumor periphery. " Order ALL the reference details at left...
3.	Fibrosis (Cirrhosis) 10/01/2002 - "CONCLUSION: Ferumoxides-enhanced gradient-echo sequences improved the diagnostic accuracy and the sensitivity for detecting malignant hepatic lesions in patients with end-stage cirrhosis of the liver. " 09/01/1999 - "CONCLUSIONS: The dose-dependency and rate of decay of efficacy of Resovist in cirrhosis were similar to those in normal liver, although the efficacy was less in cirrhotic liver and both the dose-dependency and rate of decay of efficacy were dependent on imaging parameters." 03/01/2001 - "We describe ferumoxides-enhanced magnetic resonance imaging findings in a 60-year-old man with confluent hepatic fibrosis in advanced cirrhosis. " 03/01/2001 - "Confluent hepatic fibrosis in cirrhosis: ferumoxides-enhanced MR imaging findings." 09/01/2003 - "Forty-two liver transplant candidates with end-stage cirrhosis underwent SPIO-enhanced MRI at 1.5T, using either 15 micromol/kg or 7.5 micromol/kg ferumoxides. " Order ALL the reference details at left...
4.	Neoplasm Metastasis (Metastasis) 12/01/1998 - "We conclude that ferumoxides-enhanced MR imaging is superior to unenhanced MR imaging and biphasic spiral CT for depiction of colorectal liver metastases. " 12/01/1998 - "The purpose of this study was to compare the efficacy of unenhanced and ferumoxides-enhanced magnetic resonance imaging with that of dual-phase spiral CT and spiral CT during arterial portography (CTAP) for the detection of colorectal liver metastases. " 05/01/2003 - "OBJECTIVE: The aim of this study was to compare the sensitivity of pulse inversion harmonic digital sonography, unenhanced transabdominal sonography, and ferumoxides-enhanced MR imaging in the depiction of liver metastases. " 03/01/2004 - "In our experience, Ferumoxides-enhanced MR imaging of the liver shows increased sensitivity compared to plain and spiral-CT in the evaluation of hepatic metastases. " 09/01/2003 - "The lower dose of ferumoxides was also used in 21 non-cirrhotic patients with colorectal liver metastases who acted as a control group. " Order ALL the reference details at left...
5.	Focal Nodular Hyperplasia 07/01/2000 - "CONCLUSION: Focal nodular hyperplasia shows significant decrease in signal intensity on ferumoxides-enhanced T2-weighted images, which may aid in the differentiation of focal nodular hyperplasia from other focal hepatic lesions. " 07/01/2000 - "RESULTS: Focal nodular hyperplasia showed significant signal intensity loss on ferumoxides-enhanced T2-weighted images (mean, -43%+/-6.7%, p < 0.01). " 01/01/1999 - "Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences." 01/01/1999 - "The aim of this study was to assess the efficacy of a superparamagnetic iron oxide, ferumoxides, in the detection and characterization of focal nodular hyperplasia (FNH) on MR conventional spin-echo (SE), fast spin-echo (FSE) and gradient-echo (GRE) images. " 03/01/2004 - "MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison." Order ALL the reference details at left...

Related Drugs and Biologics

1.	ferric oxide (iron oxide)
2.	Gadolinium
3.	N,N'- bis(pyridoxal- 5- phosphate)ethylenediamine- N,N'- diacetic acid (mangafodipir)
4.	Protons (Proton)
5.	TES
6.	Iron
7.	gadobenic acid (gadobenate dimeglumine)
8.	Protamines (Protamine Sulfate)
9.	ferumoxides (Feridex)
10.	Gadolinium DTPA (Magnevist)

Related Therapies and Procedures

1.	Lymph Node Excision (Lymph Node Dissection)
2.	Transplants (Transplant)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Transplantation (Transplant Recipients)
5.	Microspheres (Microsphere)

Best Treatments:
Research Summary Report
on Hepatocellular Carcinoma

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 850 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>